| Old Articles: <Older 7501-7510 Newer> |
|---|
 |
BusinessWeek
June 2, 2011
Daniel Grushkin |
Book Review: Biopunk: DIY Scientists Hack the Software of Life by Marcus Wohlsen A grass-roots movement of biohackers is ready to dream up billion-dollar ideas -- in kitchens, garages, and workshops.   |
The Motley Fool
June 2, 2011
Seth Jayson |
One Reason the Street Should Love CVS Caremark's Earnings With both 12-month and quarterly CCC running better than average, CVS Caremark gets high marks in this cash-conversion checkup. |
The Motley Fool
June 2, 2011
Dee Gill |
CVS's Improved Performance Begins to Drown Out the Dump-Caremark Chants Is the prognosis for CVS looking up? |
The Motley Fool
June 2, 2011
Luke Timmerman |
Infinity Dares to Think Big Against Pancreatic Cancer, Prepares to Show Early Results This Weekend Infinity Pharmaceuticals' top execs sometimes get strange looks when they say they are developing a new drug for pancreatic cancer. Is this a smart use of the company's time and resources? |
The Motley Fool
June 1, 2011
Brian Orelli |
Not All "Regulatory Updates" Are the Good Kind Orexigen gives an update; investors update their holdings. |
Nursing Management
June 2011
LaRocco & Pinchera |
The emerging trend of medical tourism Although it's difficult to find accurate data, there's general agreement that the number of Americans seeking medical care abroad is growing. |
The Motley Fool
June 1, 2011
Seth Jayson |
One Reason the Street Should Love Abbott Laboratories' Earnings With both 12-month and quarterly CCC running better than average, Abbott Laboratories gets high marks in this cash-conversion checkup. |
CRM
June 2011
Koa Beck |
Can Mobile Help Clarify Confusion Over Reforms? Healthcare reform has thrown everything up for question. |
The Motley Fool
May 31, 2011
Brian Orelli |
5 Biotechs With Upcoming Clinical Trial Results Investors willing to stay in these stocks a little while could see substantial gains well ahead of FDA approvals. |
The Motley Fool
May 31, 2011
David Williamson |
Roundtable: The World's Best Biotechs Motley Fool analysts choose these as their favorite biotech stocks: Aeterna Zentaris... Seattle Genetics... BioMarin Pharmaceutical... Amarin... |
| <Older 7501-7510 Newer> Return to current articles. |
